Business
Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended March 31, 2026. Congenital Hyperinsulinism (HI) In May 2026, expanded analyses from the Phase 3 sunRIZE study of ersodetug in patients with congenital HI were presented via oral pre
About this update from Rezolute, Inc.
[{"type":"image","alt":"Rezolute, Inc.","displaySize":"","headline":null,"caption":"Rezolute, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/1de9c8c904433a27065574f817efb911"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7NQ.S0SMB.pA.riFt4SSWA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/1de9c8c904433a27065574f817efb911","width":300,"height":56},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/7NQ.S0SMB.pA.riFt4SSWA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/1de9c8c904433a27065574f817efb911","width":300,"height":56}},"lazy":false},{"type":"text","content":"REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended March 31, 2026.","length":334,"tagName":"p"},{"type":"text","content":"Congenital Hyperinsulinism (HI)","length":31,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"In May 2026, expanded analyses from the Phase 3 sunRIZE study of ersodetug in patients with congenital HI were presented via oral presentation at the Pediatric Endocrine Society (PES) 2026 Annual Meeting by Diva D. De León-Crutchlow, M.D., M.S.C.E., Chief of the Division of Endocrinology and Diabetes, Director of the Congenital Hyperinsulinism Center at Children’s Hospital of Philadelphia, and Principal Investigator of the sunRIZE study.","length":446,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"In addition to the previously reported topline results, the presentation included results from additional continuous glucose monitoring (CGM)-based outcomes, which demonstrated significant and consistent improvements in glycemic control in ersodetug treatment arms compared to placebo, across multiple pre-specified and post-hoc endpoints.","length":339,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Average daily percent time in hypoglycemia by CGM: clinically relevant and nominally statistically significant reductions of >50% (Full Analysis Set...